



## Determination of subscription price

Epigenomics AG announces that the subscription price for the up to 10,806,462 ordinary registered shares with no par value (*Stückaktien*) from a capital increase against contributions in cash with subscription rights for the shareholders from the authorized capital resolved by the Executive Board on October 17, 2019, with approval of the Supervisory Board on the same day, has been determined by the Company in accordance with the principles set out in the prospectus dated October 18, 2019 and in the subscription offer dated October 21, 2019 today at

1.11 EUR

per share.

The subscription price was announced by Epigenomics AG on October 31, 2019, as insider information pursuant to Article 17 para. 1 Regulation (EU) No. 596/2014 and was published in the German Federal Gazette (*Bundesanzeiger*).

**Berlin, October 31, 2019**

**Epigenomics AG**

*The Executive Board*

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN AND AUSTRALIA.

### **Wichtige Hinweise**

*This publication does not constitute or form part of, and should not be construed as an offer or an invitation to sell, or issue or the solicitation of any offer to buy or subscribe for, any securities. The shares will be solely offered through and on the basis of the subscription offer published on October 21, 2019, and the prospectus dated October 18, 2019. The prospectus was published without undue delay on the internet website of Epigenomics AG ([www.epigenomics.com](http://www.epigenomics.com)) after approval of the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin)).*

*This publication does, in particular, not constitute an offer to sell or a solicitation of an offer to purchase any securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the laws of any state within the U.S., and may not be offered or sold in the United States or to or for the account or benefit of U.S. persons, except that the offered shares may be offered or sold to qualified institutional buyers in reliance on certain exemptions from the registration*

*requirements of the Securities Act and applicable state securities laws. This publication and the information contained herein may not be distributed or sent into the United States, or in any other jurisdiction in which offers or sales of the securities described herein would be prohibited by applicable laws and should not be distributed to United States persons or publications with a general circulation in the United States. No public offering of the shares is being made in the United States. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The securities referred to herein have not been and will not be registered under the applicable securities laws of Australia, Canada or Japan.*